Are new variants of psoriasis therapy (IL‐17 inhibitors) safe?

Psoriasis is a chronic, recurrent, inflammatory, and proliferative skin disease. Its etiology has not yet been fully assessed, but undoubtedly it is a multifaceted disease. The key role in its pathomechanism is played by genetic, immunologic, and environmental factors and stress. If traditional meth...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of dermatology Vol. 58; no. 12; pp. 1360 - 1365
Main Authors:	Wcisło‐Dziadecka, Dominika, Kaźmierczak, Agata, Grabarek, Beniamin, Zbiciak‐Nylec, Martyna, Brzezińska‐Wcisło, Ligia
Format:	Journal Article
Language:	English
Published:	England Blackwell Publishing Ltd 01.12.2019
Subjects:	Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Biological Products - administration & dosage Biological Products - adverse effects Candida - immunology Candidiasis - chemically induced Candidiasis - epidemiology Candidiasis - immunology Candidiasis - microbiology Clinical trials Clinical Trials, Phase III as Topic Cyclosporins Dermatologic Agents - administration & dosage Dermatologic Agents - adverse effects Environmental factors Etanercept Etiology Genetic engineering Humans Immunologic Factors - administration & dosage Immunologic Factors - adverse effects Incidence Infliximab Inhibitors Interleukin 17 Interleukin-17 - antagonists & inhibitors Interleukin-17 - immunology Interleukins Keratinocytes Literature reviews Methotrexate Monoclonal antibodies Nasopharyngitis - chemically induced Nasopharyngitis - epidemiology Nasopharyngitis - immunology Phosphodiesterase Phototherapy Psoriasis Psoriasis - drug therapy Psoriasis - immunology Retinoids Signs and symptoms Skin diseases Therapy Treatment Outcome Tumor necrosis factor-α
ISSN:	0011-9059, 1365-4632, 1365-4632
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!